These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24686896)

  • 1. Persistent pain facilitates response to morphine reward by downregulation of central amygdala GABAergic function.
    Zhang Z; Tao W; Hou YY; Wang W; Lu YG; Pan ZZ
    Neuropsychopharmacology; 2014 Aug; 39(9):2263-71. PubMed ID: 24686896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GluA1 in Central Amygdala Promotes Opioid Use and Reverses Inhibitory Effect of Pain.
    Hou YY; Cai YQ; Pan ZZ
    Neuroscience; 2020 Feb; 426():141-153. PubMed ID: 31863796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rewarding morphine-induced synaptic function of delta-opioid receptors on central glutamate synapses.
    Bie B; Zhu W; Pan ZZ
    J Pharmacol Exp Ther; 2009 Apr; 329(1):290-6. PubMed ID: 19168708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MeCP2 repression of G9a in regulation of pain and morphine reward.
    Zhang Z; Tao W; Hou YY; Wang W; Kenny PJ; Pan ZZ
    J Neurosci; 2014 Jul; 34(27):9076-87. PubMed ID: 24990928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central amygdala GluA1 facilitates associative learning of opioid reward.
    Cai YQ; Wang W; Hou YY; Zhang Z; Xie J; Pan ZZ
    J Neurosci; 2013 Jan; 33(4):1577-88. PubMed ID: 23345231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GABAA receptors are involved in the analgesic effects of morphine microinjected into the central nucleus of the amygdala.
    Rashvand M; Khajavai A; Parviz M; Hasanein P; Keshavarz M
    Clin Exp Pharmacol Physiol; 2014 May; 41(5):338-44. PubMed ID: 24606334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethanol-induced delta-opioid receptor modulation of glutamate synaptic transmission and conditioned place preference in central amygdala.
    Bie B; Zhu W; Pan ZZ
    Neuroscience; 2009 May; 160(2):348-58. PubMed ID: 19258026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of nerve growth factor in central amygdala increases sensitivity to opioid reward.
    Bie B; Wang Y; Cai YQ; Zhang Z; Hou YY; Pan ZZ
    Neuropsychopharmacology; 2012 Dec; 37(13):2780-8. PubMed ID: 22871918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silver nanoparticles (Ag-NPs) in the central amygdala protect the rat conditioned by morphine from withdrawal attack due to naloxone via high-level nitric oxide.
    Rahimpour M; Karami M; Haeri Rohani A
    Naunyn Schmiedebergs Arch Pharmacol; 2020 May; 393(5):857-866. PubMed ID: 31897505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of unilatral- and bilateral inhibition of rostral ventral tegmental area and central nucleus of amygdala on morphine-induced place conditioning in male Wistar rat.
    Mohammadian Z; Sahraei H; Meftahi GH; Ali-Beik H
    Clin Exp Pharmacol Physiol; 2017 Mar; 44(3):403-412. PubMed ID: 27997713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABA(A) receptors in the basolateral amygdala are involved in mediating morphine reward.
    Zarrindast MR; Ahmadi S; Haeri-Rohani A; Rezayof A; Jafari MR; Jafari-Sabet M
    Brain Res; 2004 Apr; 1006(1):49-58. PubMed ID: 15047023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient receptor potential vanilloid type 1 channel may modulate opioid reward.
    Nguyen TL; Kwon SH; Hong SI; Ma SX; Jung YH; Hwang JY; Kim HC; Lee SY; Jang CG
    Neuropsychopharmacology; 2014 Sep; 39(10):2414-22. PubMed ID: 24732880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective modulation of tonic aversive qualities of neuropathic pain by morphine in the central nucleus of the amygdala requires endogenous opioid signaling in the anterior cingulate cortex.
    Navratilova E; Nation K; Remeniuk B; Neugebauer V; Bannister K; Dickenson AH; Porreca F
    Pain; 2020 Mar; 161(3):609-618. PubMed ID: 31725062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditioned Reward of Opioids, but not Psychostimulants, is Impaired in GABA-A Receptor δ Subunit Knockout Mice.
    Siivonen MS; de Miguel E; Aaltio J; Manner AK; Vahermo M; Yli-Kauhaluoma J; Linden AM; Aitta-Aho T; Korpi ER
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):558-566. PubMed ID: 29781560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid-Induced GABA potentiation after chronic morphine attenuates the rewarding effects of opioids in the ventral tegmental area.
    Madhavan A; Bonci A; Whistler JL
    J Neurosci; 2010 Oct; 30(42):14029-35. PubMed ID: 20962224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of a new derivate of kisspeptin-10 - Kissorphin (KSO) on the rewarding effects of morphine in the conditioned place preference (CPP) test in male rats.
    Gibula-Tarlowska E; Kedzierska E; Piechura K; Silberring J; Kotlinska JH
    Behav Brain Res; 2019 Oct; 372():112043. PubMed ID: 31226311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A medial prefrontal cortex-nucleus acumens corticotropin-releasing factor circuitry for neuropathic pain-increased susceptibility to opioid reward.
    Kai Y; Li Y; Sun T; Yin W; Mao Y; Li J; Xie W; Chen S; Wang L; Li J; Zhang Z; Tao W
    Transl Psychiatry; 2018 May; 8(1):100. PubMed ID: 29780165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A leptin-mediated central mechanism in analgesia-enhanced opioid reward in rats.
    Lim G; Kim H; McCabe MF; Chou CW; Wang S; Chen LL; Marota JJ; Blood A; Breiter HC; Mao J
    J Neurosci; 2014 Jul; 34(29):9779-88. PubMed ID: 25031415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in morphine reward in a model of neuropathic pain.
    Cahill CM; Xue L; Grenier P; Magnussen C; Lecour S; Olmstead MC
    Behav Pharmacol; 2013 Jun; 24(3):207-13. PubMed ID: 23591124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.
    Grenald SA; Young MA; Wang Y; Ossipov MH; Ibrahim MM; Largent-Milnes TM; Vanderah TW
    Neuropharmacology; 2017 Apr; 116():59-70. PubMed ID: 28007501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.